# Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck

> **NCT02776137** · PHASE2 · COMPLETED · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 91 (actual)

## Conditions studied

- Head-and-neck Cancer
- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Docetaxel
- **RADIATION:** Intensity-modulated radiotherapy

## Key facts

- **NCT ID:** NCT02776137
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2017-12
- **Final completion:** 2019-02
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2020-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02776137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02776137, "Postoperative Concurrent Chemoradiotherapy With Docetaxel for High-Risk Squamous Cell Carcinoma of Head and Neck". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02776137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*